CFAR

Status

How to participate

If you are interested in participating in this study, please refer to the PEAT recruitment flyer for more information.

Study short name

PEAT

Study full name

A phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).

Principle Investigator

Mimi Tang

Administering Institute

Murdoch Children’s Research Institute

Major funding source

National Health and Medical Research Council (NHMRC)

Study focus

Treatment

Study design

Intervention

Main study aim

The aim of the study is to test the hypothesis that probiotic and egg OIT is more effective than placebo at inducing sustained unresponsiveness (remission) in participants with egg allergy 8 weeks after end-of-treatment.

Additional study information

This is a randomised, placebo-controlled trial investigating whether probiotic given in combination with egg OIT is effective at inducing sustained unresponsiveness in egg allergic children.  

Study population

The participants in this study are aged between 5 and 17 years old at time of enrolment. Participants are allergic to egg, and may have additional food allergies.

Study status

Recruitment closed.

Page last updated

17 June 2021

Study contact: [email protected]

Study Recruitment Information: PEAT Recruitment Flyer

Australia New Zealand Clinical Trials Registry: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12619000480189p